[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Pao et al., 2022 - Google Patents

Structural basis of an epitope tagging system derived from Haloarcula marismortui bacteriorhodopsin I D94N and its monoclonal antibody GD‐26

Pao et al., 2022

View PDF @Full View
Document ID
16177686430698344125
Author
Pao P
Hsu M
Chiang M
Chen C
Lee C
Wang A
Publication year
Publication venue
The FEBS Journal

External Links

Snippet

Specific antibody interactions with short peptides have made epitope tagging systems a vital tool employed in virtually all fields of biological research. Here, we present a novel epitope tagging system comprised of a monoclonal antibody named GD‐26, which recognises the …
Continue reading at febs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Similar Documents

Publication Publication Date Title
Schmitz et al. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains
Maeda et al. Development of an antibody fragment that stabilizes GPCR/G-protein complexes
Zhang et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
ES2662372T3 (en) Binding domains directed against GPCR complexes: G protein and uses derived therefrom
Piche-Nicholas et al. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
Asada et al. Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog
Reguera et al. Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies
Arimori et al. Fv-clasp: an artificially designed small antibody fragment with improved production compatibility, stability, and crystallizability
Rujas et al. Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface
US20180106790A1 (en) Single chain proteins with c-terminal modifications
Fenn et al. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain
Caillat et al. Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
Ebenhoch et al. Crystal structure and receptor-interacting residues of MYDGF—a protein mediating ischemic tissue repair
Lobner et al. Fcab-HER2 interaction: a menage a trois. Lessons from X-Ray and solution studies
Martins et al. Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics
Harris et al. An engineered switch in T cell receptor specificity leads to an unusual but functional binding geometry
Beckmann et al. DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously
Ying et al. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn
Puhl et al. Discovery and characterization of peptide inhibitors for calcium and integrin binding protein 1
Gori et al. Flexible vs rigid epitope conformations for diagnostic-and vaccine-oriented applications: novel insights from the Burkholderia pseudomallei BPSL2765 Pal3 epitope
Bazzoli et al. Using homology modeling to interrogate binding affinity in neutralization of ricin toxin by a family of single domain antibodies
Pao et al. Structural basis of an epitope tagging system derived from Haloarcula marismortui bacteriorhodopsin I D94N and its monoclonal antibody GD‐26
Frasca Biophysical characterization of antibodies with isothermal titration calorimetry
Huang et al. The smallest functional antibody fragment: ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2
Adams et al. Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides